BioPark Annual Report 2022
(No. 268) The current development of the life science companies in the BioRegioRegensburg shows a continued slightly increasing number of companies and a strong increase in the number of employees in East Bavaria in the post-Corona era. The new business figures for 2022 presented by BioPark Regensburg GmbH count 66 companies and 5,340 employees for the cluster in Eastern Bavaria.
The companies in the cluster from the fields of biotechnology, pharmaceuticals and medical engineering, diagnostics, analytics and the healthcare industry were able to continue to significantly expand their business in Eastern Bavaria in the post-Corona period and have increased their staff substantially. This is shown by the current survey in the BioRegioRegensburg, which is conducted annually by BioPark Regensburg GmbH, a company of the City of Regensburg. The total number of companies in the cluster increased slightly compared to the previous year to 66 companies (+3) (see graph 1). The total number of employees increased strongly from 4,504 to 5,340 (+16%). The BioPark is currently fully booked. The technology and start-up center currently accommodates 35 leaseholders with almost 676 employees in its three buildings on a gross area of 18,000 m2. These include start-up companies, university and non-university institutions, companies from Germany and abroad, as well as service providers and our own daycare center. The GmbH´s turnover in 2022 was €4 million.
Currently, 6 pharmaceutical companies with 1,612 employees (+85), 34 medtech companies (medical engineering, diagnostics/analytics) with 2,867 employees (+734) and 26 biotech companies with 861 (+11) employees are active in the Regensburg Bioregion cluster (see graph 2).
According to BioPark Managing Director Dr. Thomas Diefenthal, the largest increase was in medical technology. Gerresheimer, for example, received many orders for epi-pens, inhalers and syringes for vaccinations at the site. raumedic AG in the cluster region also grew strongly. Including the growth from the pharmaceutical and biotech companies, there was a total increase in employment of 836 employees (+16%) compared to the previous year. "The companies in the BioPark and city area also proudly tell us about their successes with increasing sales and business tax payments to the city of Regensburg, which now total in the double-digit millions," reports Dr. Diefenthal.
"A fine example of how the city of Regensburg and the region have created a new innovative industry of the future alongside the existing industrial sectors," comments Prof. Georg Stephan Barfuß, consultant for business, science and finance for the City of Regensburg and CFO at BioPark, on the new annual report. He sees the cluster policy initiated by the city of Regensburg, from which the BioPark also emerged over 20 years ago, as a recipe for success for the positive. In total, the business development department of the city of Regensburg has initiated ten network and cluster initiatives since 1996. Some of these work together directly in the city's two innovation and start-up centers, BioPark and TechBase, across all sectors. Particularly in the case of highly topical issues such as artificial intelligence (AI), most of the players at the location are already working together across clusters. The BioPark benefits from its location directly on the university campus with short distances to top-class research facilities at the universities and clinics.
